Tailor-made Pharma Solutions l Pharma Intelligence

Pharma Intelligence is part of the Informa Intelligence Division of Informa PLC

This is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Products:

Commercial Success

Clinical Planning

Patient Engagement & Recruitment

Regulatory & Compliance

Conferences 2022

Awards

Upcoming Webinars

Webinar recordings

Close Icon

Global Search Configuration

Search Site Products & Services
Close Icon

Search by Keyword

Focus
Needs

Tailor-made solutions

Use the expertise and experience of Pharma Intelligence to produce custom solutions that are actionable, flexible, and tailored to help you successfully navigate biopharma portfolio management, commercial optimization, and R&D strategy. Benefit from:

A customized approach – we develop solutions to fit your situation
Joint problem/opportunity definition
Proprietary data and complementary market research
The experience of 500+ industry experts
Collaborative problem solving
Fact-based decisions and actionable recommendations
Ownership of final decisions and action plans

Discover new business opportunities, reduce risks, and make better, faster decisions with tailor-made pharmaceutical solutions from Pharma Intelligence.

TrialScope Disclose

The State of Global Clinical Trial Disclosure

31 Mar 2023

The coronavirus pandemic put clinical trials in the spotlight — or hot seat, depending on one’s perspective. Around the globe pressure came from multiple fronts: regulatory agencies, the public, patients, advocates, pharmaceutical industry watchdogs and investors all clamored for increased clinical transparency. The push for accountability has not abated for study sponsors to publish results in a timely manner. However, just as there are numerous regulatory agencies and guidelines (approximately 90 countries have requirements related to the disclosure of clinical trial data made publicly available on over 30 clinical trial registries), enforcement of clinical trial disclosure requirements varies greatly.

View white paper
Scrip

Opdivos EU Colorectal Cancer is a Setback but More Than Offset By Potential Gains

By Ian Schofield 29 Nov 2022

Bristol-Myers Squibb has withdrawn its EU application to extend Opdivo’s use to metastatic colorectal cancer (mCRC), following a similar move for liver cancer last year. But the mCRC withdrawal is likely to have limited commercial impact and the company is more interested in pursuing the product’s use in combination treatment for this indication.

Topic Cancer

View article
Trial Results Summaries

AstraZeneca takes an innovative approach to trial results summaries

25 Nov 2022

What Are Trial Results Summaries and Why Are They Necessary?

Topic Clinical Trials

View case study
Trial Results Summaries

Trial results transparency starts here

25 Nov 2022

Trial Results Summaries provides an unbiased and non-promotional portal for sponsors to share trial results summaries, also known as plain language summaries (PLS), with participants and the public.

Topic Clinical Trials

View case study
Citeline, Trialtrove

2020 Clinical Trials Roundup: Disruptions to the Trial Landscape

25 Nov 2022

Our annual analysis dissects the data of all Phase I–III clinical trials that started in a year dominated by COVID-19.

Topic Coronavirus

Full webinar
5 Top Tips For Generating Successful Content Marketing

18 Nov 2022

From choosing the right audience to measuring campaign results, follow these 5 tips when planning your successful content marketing campaign.

Advertising, Marketing & Sales

View infographic
In Vivo

Bayer’s US Playbook: The Smart Way To Top-Line Growth

By William Looney 14 Nov 2022

The hotly contested US market is central to Bayer’s aspirations to become a global innovation player in pharmaceuticals, especially in key growth segments like oncology. A little more than one year in, Bayer Pharmaceuticals Americas President Dr. Carsten Brunn reflects on his unit’s progress.

Topic Business Strategies Company Analysis

View article
Medtech Insight

Inside Toyota's 'Cult' Car-Makers Quality VP Tells Device-Makers How To Adopt 4-Pronged Quality Strategy

By Shawn M. Schmitt 14 Nov 2022

Toyota Motor North America's Kristen Tabar told a roomful of medical device quality and regulatory professionals at a Case for Quality forum that they can infuse quality concepts into every nook and cranny of their firms by adopting the car-maker's quality strategy of reflection, education, celebration and planning. "I don’t want to make it sound like it’s sort of cult-y, but it’s kind of cult-y," Tabar quipped.

Topic Company Analysis Strategy

View article
Scrip

Pfizer Lays Out Multi-Phase COVID-19 Vaccine Commercial Strategy

By Jessica Merrill 14 Nov 2022

The pandemic phase will last through late 2021/early 2022, becoming a more seasonal opportunity for several years after, Pfizer management predicted during the company's second quarter call.

Topic Coronavirus Vaccines Sales Earnings

View article
Datamonitor Healthcare

Multiple Myeloma Pricing, Reimbursement, and Access

14 Nov 2022

Disease management and treatment programmes change, as research evolves and new discoveries are made. Your market access strategies must evolve too.

Topic Cancer Drug Development Landscape Reimbursement

View infographic
Scrip

Sanofi's €10bn Dupixent Plan: 'We're Going To Put The JAKs Properly In Their Place'

By Jessica Merrill 14 Nov 2022

Sanofi's new CEO has ambitious forecasts for Dupixent in atopic dermatitis, asthma and other indications. The French pharma outlined how it plans to reach that goal despite new competition vying to get in.

Topic Business Strategies Immune Disorders Inflammation

View article
In Vivo

Critical Insights into Market Access

14 Nov 2022

Your key to refining your market access strategy with essential patient market access mini-mag and infographic from the experts at In Vivo.

View infographic
In Vivo

From US To EU: Young Biotechs Going It Alone

By Jo Shorthouse 14 Nov 2022

Europe’s patchwork of reimbursement agencies make it a daunting place for a small US biotech to do business. Traditionally large pharma partners or CMSOs have provided an experienced hand to hold, but as a new wave of gene therapies and orphan drugs get the EMA green light, smaller drug developers are applying innovation to commercialization and choosing to go solo.

Topic Market Access Rare Diseases Strategy

View analysis
Scrip

Progress Being Made With Cell And Gene Therapy Market Access, But Challenges Remain

By Mandy Jackson 14 Nov 2022

Drug developers and payers are coming together long before product approvals to work out payment options for high-cost, high-impact cell and gene therapies, but challenges like portability of commercially insured patients and Medicaid best price requirements remain.

Topic Cell & Gene Therapy Drug Development Landscape

View article
Datamonitor Healthcare

Acute Myeloid Leukemia Market Outlook Seminar

By Dominique Fontanilla 14 Nov 2022

There has been little change to standard treatment for AML in recent years; however, 2017 saw a flurry of new targeted drug approvals, sparking significant market growth. Patient age remains the biggest factor in driving treatment decisions for AML. Cases of AML are expected to increase, and prognosis remains poor – especially among older adults. Drug developers are targeting patient segments with high unmet clinical need to gain access to the AML market and the budget impact of AML is expected to grow considerably.

Topic Cancer

Full video

Latest headlines

Generics Bulletin

05 Jun 2023

AMR Alliance Follows Up Global Industry Standard With Responsible Manufacturing Certification

Link
Medtech Insight

05 Jun 2023

Exec Chat: PacBio Addresses Latest Results, New Tech And Long-Read Sequencing’s Future

Link
Medtech Insight

05 Jun 2023

MedTech Forum 2023: Europe’s Regulatory Maze Must Be Simplified, But How?

Link
Scrip

05 Jun 2023

China Roundup: Rare Disease Approvals, Local mRNA Shots, CEO Visits

Link
Scrip

04 Jun 2023

ASCO 2023 – Trop2 Could Validate Merck’s Savvy Deal With Kelun

Link
Scrip

04 Jun 2023

ASCO - Servier’s Vorasidenib Puts The Brakes On Brain Cancer In INDIGO

Link
Scrip

04 Jun 2023

ASCO 2023 - Servier’s Vorasidenib Puts The Brakes On Brain Cancer In INDIGO

Link
Scrip

04 Jun 2023

ASCO 2023 – Deep And Early Responses Lift Hopes At Effector

Link
HBW Insight

04 Jun 2023

EWG’s 2023 Sunscreen Guide: Oxybenzone Use Down, ‘EWG Verified’ Products Up

Link
Scrip

04 Jun 2023

ImmunoGen’s Elahere Data In Avastin-Naïve Ovarian Cancer Prompt Discussion About Earlier Use

Link
Scrip

03 Jun 2023

ASCO 2023 – A Role For Immuno-Oncology In Ovarian Cancer At Last?

Link
Scrip

03 Jun 2023

ASCO 2023 – Pfizer Pushes Forward In Drug-Resistant Breast Cancer

Link
Scrip

03 Jun 2023

ASCO 2023 – Elevation follows in Astellas’s slipstream

Link
Scrip

03 Jun 2023

Jazz Hits High Note With Updated Zanidatamab Data In Biliary Tract Cancer At ASCO

Link
Medtech Insight

02 Jun 2023

Global Medtech Guidance Tracker: May 2023

Link

Next steps

Request a live demo

Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.

Request live demo now:

Request a free demo

Speak to Sales

Our team is ready to hear from you for a particular request or area of interest. Please do not hesitate to reach out and discuss.

Contact Sales

Client Services

US Toll-Free : +1 888 670 8900
US Toll : +1 212-600-3520
UK & Europe : +44 (0) 208 052 0700

Contact Customer Services

Pharma Report Store

Have an immediate and specific information need?

Browse and buy from 1000s of analysis and research reports now:

Shop now

Tailor-made Pharma Solutions

Tailor-made solutions

Pharma Intelligence latest insights

The State of Global Clinical Trial Disclosure

Opdivos EU Colorectal Cancer is a Setback but More Than Offset By Potential Gains

AstraZeneca takes an innovative approach to trial results summaries

Trial results transparency starts here

2020 Clinical Trials Roundup: Disruptions to the Trial Landscape

5 Top Tips For Generating Successful Content Marketing

Bayer’s US Playbook: The Smart Way To Top-Line Growth

Inside Toyota's 'Cult' Car-Makers Quality VP Tells Device-Makers How To Adopt 4-Pronged Quality Strategy

Pfizer Lays Out Multi-Phase COVID-19 Vaccine Commercial Strategy

Multiple Myeloma Pricing, Reimbursement, and Access

Sanofi's €10bn Dupixent Plan: 'We're Going To Put The JAKs Properly In Their Place'

Critical Insights into Market Access

From US To EU: Young Biotechs Going It Alone

Progress Being Made With Cell And Gene Therapy Market Access, But Challenges Remain

Acute Myeloid Leukemia Market Outlook Seminar

Latest headlines

AMR Alliance Follows Up Global Industry Standard With Responsible Manufacturing Certification

Exec Chat: PacBio Addresses Latest Results, New Tech And Long-Read Sequencing’s Future

MedTech Forum 2023: Europe’s Regulatory Maze Must Be Simplified, But How?

China Roundup: Rare Disease Approvals, Local mRNA Shots, CEO Visits

ASCO 2023 – Trop2 Could Validate Merck’s Savvy Deal With Kelun

ASCO - Servier’s Vorasidenib Puts The Brakes On Brain Cancer In INDIGO

ASCO 2023 - Servier’s Vorasidenib Puts The Brakes On Brain Cancer In INDIGO

ASCO 2023 – Deep And Early Responses Lift Hopes At Effector

EWG’s 2023 Sunscreen Guide: Oxybenzone Use Down, ‘EWG Verified’ Products Up

ImmunoGen’s Elahere Data In Avastin-Naïve Ovarian Cancer Prompt Discussion About Earlier Use

ASCO 2023 – A Role For Immuno-Oncology In Ovarian Cancer At Last?

ASCO 2023 – Pfizer Pushes Forward In Drug-Resistant Breast Cancer

ASCO 2023 – Elevation follows in Astellas’s slipstream

Jazz Hits High Note With Updated Zanidatamab Data In Biliary Tract Cancer At ASCO

Global Medtech Guidance Tracker: May 2023

Next steps

This is Contactus Section

Request a live demo

Speak to Sales

Client Services

Pharma Report Store